- Home
- PRFX vs CHEK Comparison
PRFX vs CHEK Comparison
Compare PRFX & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- CHEK
- Stock Information
- Founded
- PRFX 2007
- CHEK 2004
- Country
- PRFX Israel
- CHEK Israel
- Employees
- PRFX N/A
- CHEK N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- CHEK Medical Electronics
- Sector
- PRFX Health Care
- CHEK Health Care
- Exchange
- PRFX Nasdaq
- CHEK Nasdaq
- Market Cap
- PRFX 3.8M
- CHEK 4.0M
- IPO Year
- PRFX 2020
- CHEK 2015
- Fundamental
- Price
- PRFX $1.88
- CHEK $0.82
- Analyst Decision
- PRFX Hold
- CHEK
- Analyst Count
- PRFX 1
- CHEK 0
- Target Price
- PRFX N/A
- CHEK N/A
- AVG Volume (30 Days)
- PRFX 3.8M
- CHEK 76.0K
- Earning Date
- PRFX 05-14-2025
- CHEK 05-20-2025
- Dividend Yield
- PRFX N/A
- CHEK N/A
- EPS Growth
- PRFX N/A
- CHEK N/A
- EPS
- PRFX N/A
- CHEK N/A
- Revenue
- PRFX N/A
- CHEK N/A
- Revenue This Year
- PRFX N/A
- CHEK N/A
- Revenue Next Year
- PRFX N/A
- CHEK N/A
- P/E Ratio
- PRFX N/A
- CHEK N/A
- Revenue Growth
- PRFX N/A
- CHEK N/A
- 52 Week Low
- PRFX $0.43
- CHEK $0.56
- 52 Week High
- PRFX $16.63
- CHEK $3.04
- Technical
- Relative Strength Index (RSI)
- PRFX 34.67
- CHEK 56.80
- Support Level
- PRFX $2.22
- CHEK $0.73
- Resistance Level
- PRFX $2.41
- CHEK $1.11
- Average True Range (ATR)
- PRFX 0.14
- CHEK 0.10
- MACD
- PRFX -0.02
- CHEK 0.03
- Stochastic Oscillator
- PRFX 6.80
- CHEK 51.37
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.